15 October 2020
Health authorities in Russia have approved a second Covid-19 vaccine before the Phase 3 trial. The vaccine has been created by a former bio-weapons research laboratory. This is the second time the country has bypassed approval of the drug in a desperate move to control the rising coronavirus cases.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Moderna has received a confirmation from the European Medicine Agency (EMA) to apply for a European Union marketing authorisation for its Covid-19 vaccine candidate, mRNA-1273. This followed a letter of intent submitted to allow Moderna to evaluate the prospect of submitting a Marketing Authorisation Application (MAA) for the vaccine candidate with the EMA.
Turkey is set to conduct human trials for two of its potential Covid-19 vaccines. According to the Health Minister Fahrettin Koca, these vaccine candidates are being developed locally. Approximately, 14 institutions are currently engaged in the research of a vaccine to fight the novel coronavirus disease, reported Hurriyet Daily News. There have been positive results from the pre-clinical and clinical phases of the vaccine development, Koca added.
Relief Therapeutics and NeuroRx have announced topline results from an open-label study of RLF-100 for Covid-19. In the study, 21 critical patients with respiratory failure and hospitalised in the ICU were treated with RLF-100 and were compared to 24 control patients. The study found that an overall 81% of RLF-100-treated patients survived beyond 60 days, compared to 17% of control patients. Patients who were treated with RLF-100 showed a nine-fold increase in probability of survival and recovery from respiratory failure.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
